Stock Report

All about this stock under one free report Last Updated: 02-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Aarti Drugs Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: AARTIDRUGS | BSE: 524348

₹427.10

up-down-arrow ₹15.40 (3.74%)

As on 01-Sep-2026IST

Market cap

info icon

₹3,894 Cr

Revenue (TTM)

info icon

₹2,678 Cr

P/E Ratio

info icon

20.4

P/B Ratio

info icon

2.4

Div. Yield

info icon

0.5 %

Edit peer-selector-edit
Aarti Drugs Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Market cap (₹ Cr)
 3,894 35,015 29,555 17,723 15,518
Revenue (₹ Cr)
 2,678 9,683 2,372 2,590 1,108
Net Profit (₹ Cr)
 191.10 1,018.97 497.77 603.02 270.18
Net Margin (%)
 7.13 10.47 20.72 22.63 23.29
RoE (%)
 12.77 21.30 28.49 19.61 14.45
Price to Earnings
 20.37 34.62 59.37 29.39 56.35
Price-To-Book
 2.44 6.69 14.62 5.09 7.48

Income Statement (₹ Cr)

Aarti Drugs Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Operating Revenue arrow
2,677.58 9,683.45 2,371.81 2,590.40 1,108.39
Total Income arrow
2,680.47 9,730.84 2,402.61 2,664.23 1,159.90
Total Expenditure arrow
2,344.26 7,739.53 1,608.91 1,753.71 720.01
EBITDA arrow
333.32 1,943.92 762.90 836.69 388.38
Depreciation arrow
70.71 425.10 98.11 78.88 74.78
EBIT arrow
262.61 1,518.82 664.79 757.81 313.60
Interest arrow
34.37 148.45 26.33 5.43 0.26
Other Income arrow
2.89 47.39 30.80 73.83 51.50
Exceptional Items arrow
-2.09 -27.85 0.00 -25.66 -3.28
Profit before Tax arrow
229.04 1,389.91 669.26 800.55 361.56
Provision for Tax arrow
37.94 370.94 171.48 197.53 91.39
Profit after Tax arrow
191.10 1,018.97 497.77 603.02 270.18

Liabilities (₹ Cr)

Aarti Drugs Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Shareholder's Funds arrow
1,548.86 4,950.03 1,874.47 3,332.13 2,017.06
Minority Interest arrow
0.08 -7.58 0.00 0.00 2.51
Non-Current Liabilities arrow
343.78 723.57 345.47 142.73 50.51
Current Liabilities arrow
922.26 3,912.24 710.20 508.04 169.08
Total Liabilities arrow
2,574.68 8,121.73 2,179.88 3,753.59 2,034.25

Assets (₹ Cr)

Aarti Drugs Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Non-Current Assets arrow
1,325.82 3,392.16 1,290.62 1,321.38 957.22
Current Assets arrow
1,467.77 5,612.10 1,483.13 2,649.36 1,250.11
Total Assets arrow
2,574.68 8,121.73 2,179.88 3,753.59 2,034.25
Total Debt* arrow
612.24 731.70 136.01 0.00 0.38
Net Current Assets arrow
545.51 1,699.86 772.93 2,141.33 1,081.04
Contingent Liabilities arrow
281.69 393.94 8.97 4.82 3.91

Cashflow (₹ Cr)

Aarti Drugs Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Cash From Operating Activities arrow
244.58 851.71 317.40 391.52 244.52
Cash Flow from Investing Activities arrow
-164.63 -94.00 -298.16 -615.65 -159.99
Cash from Financing Activities arrow
-82.12 -813.96 24.96 -6.23 -98.77
Net Cash Inflow / Outflow arrow
-2.17 -56.25 44.21 -230.35 -14.24

Ratios

Profitability Ratios

 Aarti Drugs Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
ROCE (%) arrow
13.11 22.49 23.45 25.50 29.62
ROE (%) arrow
12.77 21.30 28.49 19.61 14.45
ROA (%) arrow
7.09 11.42 19.48 16.31 12.66
EBIT Margin (%) arrow
9.81 15.68 28.03 29.25 28.29
Net Margin (%) arrow
7.13 10.47 20.72 22.63 23.29
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Aarti Drugs Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Revenue Growth (%) arrow
10.54 18.36 78.33 7.93 -6.72
EBIT Growth (%) arrow
9.85 30.43 303.07 19.88 -26.64
Net Profit Growth (%) arrow
1.22 32.39 182.61 21.66 -24.38
EPS Growth (%) arrow
2.05 36.68 277.72 25.42 -21.99
Book Value Growth (%) arrow
6.82 50.94 18.89 20.94 18.74

Valuation Ratios

 Aarti Drugs Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Price / Earnings arrow
20.21 33.91 59.37 28.46 55.86
Price / Book Value arrow
2.44 6.69 14.62 5.09 7.48
Dividend Yield (%) arrow
0.47 0.20 0.15 0.35 0.51
EV/EBITDA arrow
13.50 18.56 38.53 20.25 38.88
Market Cap (₹ Cr) arrow
3,101.47 20,327.45 15,494.53 13,228.83 17,537.35

Solvency Ratios

 Aarti Drugs Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debt to Equity arrow
0.17 0.05 0.09 0.00 0.00
Short term debt to equity ratio arrow
0.20 0.11 -- -- 0.00
Current Ratio arrow
1.59 1.43 2.09 5.21 7.39
Quick Ratio arrow
1.06 0.82 1.37 3.85 5.46
Interest Coverage arrow
7.66 10.36 26.41 148.49 1,386.30

Operating Efficiency Ratios

 Aarti Drugs Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debtors to sales (%) arrow
30.99 26.46 22.82 41.42 41.52
Asset Turnover arrow
0.99 1.09 0.93 0.70 0.52
Receivable days arrow
111.30 87.83 85.17 132.12 132.49
Inventory Days arrow
73.31 78.64 90.97 102.08 68.07
Payable days arrow
104.72 174.97 137.94 133.54 123.94
Cash Conversion Cycle arrow
79.88 -8.50 38.21 100.66 76.63
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...